BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

RxKinetix, Inc. And Indian Immunologicals Limited Collaborate On Development Of Thermostable Hepatitis B Vaccines


11/2/2005 1:12:38 PM

LOUISVILLE, Colo., Nov. 2 /PRNewswire/ -- RxKinetix Inc., a specialty pharmaceutical company developing new therapeutics focused on un-met needs in oncology care, and Indian Immunologicals Ltd, a leading manufacturer of veterinary and human vaccines, today announced they will collaborate in the development of thermostable Hepatitis B vaccines with improved stability at non-refrigerated temperatures. This project is funded by a grant awarded to RxKinetix from the Foundation for the National Institutes of Health through the Grand Challenges in Global Health Initiative.

As part of the collaboration, Indian Immunologicals Limited will supply RxKinetix with Hepatitis B vaccine, which will be formulated by RxKinetix in its ProJuvant(TM) vaccine delivery platform and tested for thermostability. Formulations showing good potential will then be tested in vivo.

"Indian Immunologicals is an ideal collaborator for RxKinetix in this project," said Marazban Sarkari, Ph.D., Principal Investigator for the Grand Challenges Grant. "They are aggressively pursuing a strategy that would increase vaccinations to improve health in India and other Asian countries and so they have a great interest in seeing this project succeed."

"We are very pleased to be working with RxKinetix," said Dr. V. A. Srinivasan, Research Director, Indian Immunologicals Limited. "Their ProJuvant technology has shown real promise in improving the efficacy of certain vaccines. The additional demonstration of thermostability will mean these vaccines could potentially be of great value, especially in tropical countries."

About RxKinetix

RxKinetix, Inc. is a specialty pharmaceutical company developing new therapeutics focused in oncology care. Using proven pharmaceuticals and proprietary polymer-based drug delivery technologies, RxKinetix creates new drugs or enhances existing drugs. The Company's strategy improves timelines and reduces risk during clinical development. RxKinetix has a strong intellectual property portfolio in support of its products and technologies. More information regarding RxKinetix is available at www.rxkinetix.com.

About Indian Immunologicals

Indian Immunologicals Limited (IIL) is a wholly owned subsidiary of the National Dairy Development Board and was set up in 1983 to manufacture Foot and Mouth Disease (FMD) vaccine in India. IIL is the fifth largest player in the animal health market in India and the market leader in veterinary vaccines. Human Biologicals Institute (HBI), a division of Indian Immunologicals Limited, manufactures purified Vero cell rabies vaccine (PVRV) marketed under the brand name 'Abhayrab' and is shortly planning to launch a range of pediatric vaccines, including hepatitis B and combinations. More information regarding Indian Immunologicals is available at www.indimmune.com.

RxKinetix Inc.

CONTACT: Joanna K. Money, Ph.D., VP, Corporate Development of RxKinetix,+1-303-926-1900, or Email, jmoney@rxkinetix.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES